IMU fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
IMU does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company